BRPI0921249A8 - uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterápico na preparação de uma composição, e composições para o tratamento do cãncer - Google Patents

uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterápico na preparação de uma composição, e composições para o tratamento do cãncer

Info

Publication number
BRPI0921249A8
BRPI0921249A8 BRPI0921249A BRPI0921249A BRPI0921249A8 BR PI0921249 A8 BRPI0921249 A8 BR PI0921249A8 BR PI0921249 A BRPI0921249 A BR PI0921249A BR PI0921249 A BRPI0921249 A BR PI0921249A BR PI0921249 A8 BRPI0921249 A8 BR PI0921249A8
Authority
BR
Brazil
Prior art keywords
preparation
composition
extracellular matrix
compositions
chemotherapeutic agent
Prior art date
Application number
BRPI0921249A
Other languages
English (en)
Inventor
Pinney Emmett
K Naughton Gail
Original Assignee
Histogen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Histogen Inc filed Critical Histogen Inc
Publication of BRPI0921249A2 publication Critical patent/BRPI0921249A2/pt
Publication of BRPI0921249A8 publication Critical patent/BRPI0921249A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A61K31/282—Platinum compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/13—Tumour cells, irrespective of tissue of origin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/54—Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Gynecology & Obstetrics (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0921249A 2008-11-14 2009-01-30 uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterápico na preparação de uma composição, e composições para o tratamento do cãncer BRPI0921249A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US11496608P 2008-11-14 2008-11-14
US61/114.966 2008-11-14
PCT/US2009/032677 WO2010056378A2 (en) 2008-11-14 2009-01-30 Extracellular matrix compositions for the treatment of cancer

Publications (2)

Publication Number Publication Date
BRPI0921249A2 BRPI0921249A2 (pt) 2018-10-23
BRPI0921249A8 true BRPI0921249A8 (pt) 2018-12-04

Family

ID=42170608

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921249A BRPI0921249A8 (pt) 2008-11-14 2009-01-30 uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterápico na preparação de uma composição, e composições para o tratamento do cãncer

Country Status (10)

Country Link
US (6) US8852637B2 (pt)
EP (1) EP2365815B1 (pt)
JP (1) JP5916388B2 (pt)
KR (1) KR101610985B1 (pt)
CN (1) CN102497871B (pt)
AU (1) AU2009314506B2 (pt)
BR (1) BRPI0921249A8 (pt)
CA (1) CA2743871C (pt)
RU (1) RU2523339C2 (pt)
WO (1) WO2010056378A2 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9283266B2 (en) * 2008-02-28 2016-03-15 University Of Notre Dame Metastasis inhibition preparations and methods
KR101610985B1 (ko) 2008-11-14 2016-04-08 히스토젠, 인코포레이티드 암 치료를 위한 세포외 기질 조성물
WO2013003234A1 (en) * 2011-06-28 2013-01-03 Trevigen, Inc. Tumor extract
EP2816964B1 (en) 2012-02-21 2023-12-27 Ben-Gurion University of The Negev Research and Development Authority Hydrogel system comprising spatially separated bioactive polypeptides
US20140248371A1 (en) * 2013-01-10 2014-09-04 Carmel-Haifa University Economic Corp. Ltd. Spalax fibroblast-derived anti-cancer agents
RU2678878C2 (ru) 2013-02-12 2019-02-05 Репликэл Лайф Сайенсиз Инк. Композиции и способы для лечения и восстановления сухожилий
US10533191B2 (en) 2014-01-15 2020-01-14 Serucell Corporation Therapeutic serum obtained from co-cultured cells
TW201538730A (zh) 2014-02-12 2015-10-16 Replicel Life Sciences Inc 用於治療骨骼、關節及軟骨之組合物及方法
KR102440051B1 (ko) 2014-03-21 2022-09-06 유니버시티 오브 피츠버그 - 오브 더 커먼웰쓰 시스템 오브 하이어 에듀케이션 세포외 기질로부터 유래한 최종 멸균된 하이드로겔의 제조 방법
EP3288565A4 (en) * 2015-04-30 2019-02-13 Histogen, Inc. EXTRACELLULAR MATRIX COMPOSITIONS FOR THE TREATMENT OF CANCER OR IMMUNE DISEASES
US11123404B2 (en) 2016-01-07 2021-09-21 B. G. Negev Technologies And Applications Ltd., At Ben-Gurion University Methods for generating immunotolerant responses
JP6757578B2 (ja) * 2016-03-15 2020-09-23 メビオール株式会社 Ｔｇｐ含有保存液と微小重力負荷による免疫細胞及び血液細胞の機能増強方法
CA3020400A1 (en) * 2016-04-12 2017-10-19 Illustris Pharmaceuticals, Inc. Compositions for topical application of compounds
EP3589294B1 (en) * 2017-03-02 2022-10-26 University of Pittsburgh - Of the Commonwealth System of Higher Education Extracellular matrix (ecm) hydrogel and soluble fraction thereof for use in the treatment of cancer
CN107349417A (zh) * 2017-04-01 2017-11-17 南阳市中心医院 一种治疗食管鳞癌的ecm复合物以及其在制备治疗食管鳞癌的药物中的用途
US11718829B2 (en) 2017-07-28 2023-08-08 Breakthrough Tech Llc Methods and compositions for manufacturing extracellular matrix
CA3078631A1 (en) * 2017-10-11 2019-04-18 Jacob M. Waugh Methods and compositions for topical delivery
CN108424878A (zh) * 2018-03-26 2018-08-21 南通大学附属医院 乳腺癌及乳腺组织ecm及其制备方法和乳腺癌3d体外培养模型的构建方法
WO2020028526A1 (en) * 2018-08-02 2020-02-06 Histogen, Inc. Conditioned medium and extracellular matrix compositions and uses thereof
KR20200040536A (ko) * 2018-10-10 2020-04-20 사회복지법인 삼성생명공익재단 저산소 조건에서 섬유아세포를 배양하여 제조한 조정배지를 포함하는 암세포 사멸 유도용 조성물 및 이의 제조 방법
US20210000910A1 (en) 2019-07-03 2021-01-07 Jysk Skin Solutions Pte Ltd Topical compositions
US12077780B2 (en) 2020-02-14 2024-09-03 Allergan Sales, Llc Conditioned medium from cells cultured under hypoxic conditions and uses thereof
TWI888659B (zh) * 2021-10-13 2025-07-01 芯芮生技開發股份有限公司 幹細胞條件培養基於製備抑制癌症組成物的用途
US12083204B2 (en) 2022-06-02 2024-09-10 L'oreal Topical composition for homeostatic delivery of nitric oxide and uses thereof
BE1031361B1 (fr) * 2023-02-20 2024-09-23 Novadip Biosciences Utilisation d'une composition comprenant une matrice extracellulaire neo-synthetisee pour le traitement du cancer, en particulier pour l'inhibition de la viabilite, de la migration et de la proliferation du cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5032508A (en) * 1988-09-08 1991-07-16 Marrow-Tech, Inc. Three-dimensional cell and tissue culture system
US5902741A (en) 1986-04-18 1999-05-11 Advanced Tissue Sciences, Inc. Three-dimensional cartilage cultures
US5863531A (en) * 1986-04-18 1999-01-26 Advanced Tissue Sciences, Inc. In vitro preparation of tubular tissue structures by stromal cell culture on a three-dimensional framework
CA2122519C (en) * 1994-04-29 2001-02-20 Rudolf Edgar Dr. Falk Cancer treatment and metastasis prevention
US5750146A (en) * 1995-04-28 1998-05-12 Matrix Pharmaceutical, Inc. Translucent collagen formulations with a cytotoxic drug
US5830708A (en) * 1995-06-06 1998-11-03 Advanced Tissue Sciences, Inc. Methods for production of a naturally secreted extracellular matrix
KR19980068378A (ko) 1997-02-19 1998-10-15 김광호 액정 프로젝터의 광학장치
US6197586B1 (en) * 1997-12-12 2001-03-06 The Regents Of The University Of California Chondrocyte-like cells useful for tissue engineering and methods
BR9909393A (pt) 1998-04-03 2000-12-26 Ajinomoto Kk Agente antitumor, uso de um derivado de estilbeno e um composto de coordenação de platina, e, processo para o tratamento ou melhoramento de um tumor
BR9915476A (pt) * 1998-11-19 2002-01-02 Organogenesis Inc Construtos de tecidos feitos por bioengenharia e métodos para a sua produção e utilização
US6372494B1 (en) * 1999-05-14 2002-04-16 Advanced Tissue Sciences, Inc. Methods of making conditioned cell culture medium compositions
RU2311892C2 (ru) 2001-08-29 2007-12-10 КАРВАЛХО Рикардо А. П. ДЕ Имплантируемая и герметизируемая система для однонаправленной доставки терапевтических препаратов в ткани
US20040076622A1 (en) * 2002-03-02 2004-04-22 Board Of Regents, The University Of Texas System Local production and/or delivery of anti-cancer agents by stromal cell precursors
EP1727893B1 (en) * 2004-03-09 2012-12-12 Jan-Eric W. Ahlfors Autogenic living scaffolds and living tissue matrices: methods and uses thereof
WO2005104766A2 (en) * 2004-04-28 2005-11-10 Myocardial Therapeutics, Inc. Injection of bone marrow-derived conditioned medium for angiogenesis
US8685724B2 (en) * 2004-06-01 2014-04-01 Kwalata Trading Limited In vitro techniques for use with stem cells
WO2006026730A2 (en) * 2004-08-30 2006-03-09 Iken Tissue Therapeutics, Inc. Cultured three dimensional tissues and uses thereof
WO2006052852A2 (en) 2004-11-04 2006-05-18 Hemogenix, Inc. Kit for in process quality control to predict and determine engraftment and multilineage reconstitution potential of hematopoietic cells and cord blood storage
ATE500855T1 (de) 2004-11-22 2011-03-15 Theregen Inc Vewendung von dreidimensionalem kultiviertem gewebe zur behandlung von kongestivem herzversagen
EP1831254B1 (en) * 2004-12-23 2012-06-06 Molmed SpA Conjugation product
JP2006249031A (ja) 2005-03-11 2006-09-21 Tokyo Univ Of Science 抗癌剤
JP2009508650A (ja) * 2005-09-21 2009-03-05 ダスク テクノロジーズ， エルエルシー 臓器および組織機能のための方法および組成
US7674770B2 (en) 2007-04-11 2010-03-09 Gene Signal International Sa Anti-tumor drug, medicament, composition, and use thereof
KR101610985B1 (ko) 2008-11-14 2016-04-08 히스토젠, 인코포레이티드 암 치료를 위한 세포외 기질 조성물

Also Published As

Publication number Publication date
EP2365815A4 (en) 2016-11-30
US20100124573A1 (en) 2010-05-20
CN102497871A (zh) 2012-06-13
US20170071985A1 (en) 2017-03-16
US20190201439A1 (en) 2019-07-04
JP2012508739A (ja) 2012-04-12
US9506038B2 (en) 2016-11-29
WO2010056378A3 (en) 2015-10-08
KR20110106302A (ko) 2011-09-28
US20110097403A1 (en) 2011-04-28
US10143708B2 (en) 2018-12-04
CA2743871A1 (en) 2010-05-20
AU2009314506B2 (en) 2015-07-23
US8852637B2 (en) 2014-10-07
RU2523339C2 (ru) 2014-07-20
RU2011123788A (ru) 2012-12-20
BRPI0921249A2 (pt) 2018-10-23
WO2010056378A2 (en) 2010-05-20
US9034312B2 (en) 2015-05-19
CN102497871B (zh) 2014-10-15
EP2365815B1 (en) 2019-09-18
AU2009314506A1 (en) 2010-05-20
CA2743871C (en) 2016-10-11
EP2365815A2 (en) 2011-09-21
US20200360430A1 (en) 2020-11-19
US20150246076A1 (en) 2015-09-03
JP5916388B2 (ja) 2016-05-11
KR101610985B1 (ko) 2016-04-08
US10675303B2 (en) 2020-06-09

Similar Documents

Publication Publication Date Title
BRPI0921249A2 (pt) uso de matriz extracelular na preparação de uma composição,uso de matriz extracelular e agente quimioterapico na preparação de uma composição,e composições para o tratamento do cãncer.
BRPI0908503A2 (pt) partícula com um diâmetro menor que 2mm, e, composição para o tratamento de tecidos
BRPI1010903A2 (pt) partícula modificada na superfície, composição farmacêutica, método para intensificar a absorção celular de um agente ativo, uso de uma pluralidade de partículas modificadas na superfície, e, pluralidade de partículas modificadas na superfície
BRPI0822220A2 (pt) Composições contendo enzima e agente de matiz para tecidos
BRPI0820899A2 (pt) Formulação cosmética, e, uso da composição
BR112012016398A2 (pt) Composto imidazopiridinil-aminopiridino substituído, composição farmacêutica que compreende o referido composto e uso do mesmo para o tratamento de uma doença celular proliferativa
BR112014019011A8 (pt) Composição, método para controlar a umectabilidade das superfícies do substrato, uso de uma composição, e, material
BRPI0920955A2 (pt) processo para a preparação de uma composição polimérica , composição polimérica, misturas, e, uso da composição polimérica
BRPI0906576A2 (pt) Composição farmacêutica, kit, uso de um composto, e, agente terapêutico para câncer
BR112012001381A2 (pt) uso de uma mistura de uma dispersão aquosa de partículas orgânicas ocas, material de revestimento na forma de uma composição aquosa, e, material de revestimento
BRPI0813680A8 (pt) composição compreendendo um agente de irna para alfa-enac, constituído por um fita senso e uma fita antissenso, e seu uso
CL2013003455A1 (es) Uso de compuestos inhibidores de sglt-2 derivados de benceno, sustituidos por glucopiranosilo para prevenir, desacelerar la progresion, retrasar o tratar un trastorno metabolico en un pacientes con un agente neuroleptico; uso de la combinacion del inhibidor de sglt2 con un neuroleptico; y composicion farmaceutica de la combinacion.
BRPI0911297A2 (pt) composição e métodos para preparo e uso das mesmas
BRPI0922587A2 (pt) composição detergente para lavagem, e, uso da composição citada
IL205318A0 (en) Compositions comprising electrochemically altered aqueous fluids and uses thereof for treating inflammation
BR112012008854A2 (pt) combinação, kit de combinação, uso de uma combinação, composição farmacêutica, e, método para tratar câncer em um ser humano
BRPI0907663A8 (pt) composição que compreende hfo- 123 yf, composição que compreende hcfc-243db, composição que compreende hcfo- 1233xf, composição que comproeende hcfc- 244bb, uso das composições e método de uso das composições
CL2013000396A1 (es) Composicion que comprende bacillus subtilis y bacillus licheniformis; proceso para elaborar dicha composicion; uso de dicha composición para el control de los fitonematodos y/o en la introduccion de una resistencia especifica a ellos.
CL2007003226A1 (es) Compuestos derivados de piridinona; composicion farmaceutica; y uso para tratar el cancer.
BRPI0807220B1 (pt) composição, e, métodos para aumentar a força de compressão de uma composição e para aumentar a retenção de fragrância de uma composição
BRPI0816948A2 (pt) Composição fungicida para controlar fungos nocivos fitopatogênicos, agente fungicida, método para controlar fungos nocivos fitopatogênicos, semente, e, uso dos componentes
BRPI0908792A2 (pt) Composição, e, uso de uma combinação
BRPI0907871A2 (pt) Artigo absorvente que compreende composição de loção que compreende um agente de resfriamento
BRPI0813456A2 (pt) Composto, uso do mesmo, composição farmacêutica, e, métodos para tratar um mamífero sofrendo de um distúrbio e de uma doença
CL2008002381A1 (es) Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.

Legal Events

Date Code Title Description
B08E Application fees: payment of additional fee required [chapter 8.5 patent gazette]

Free format text: COMPLEMENTAR A RETRIBUICAO DA 6A, 7A 8A E 9A ANUIDADES, DE ACORDO COM TABELA VIGENTE, REFERENTE AS GUIAS DE RECOLHIMENTO 0000921500701490, 0000921600783790, 0000921700864377 E 29409161801083524, RESPECTIVAMENTE.

B08H Application fees: decision cancelled [chapter 8.8 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 8.5 NA RPI NO 2498 DE 21/11/2018.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL